Navigation Links
Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
Date:4/15/2009

Only 39 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources

WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed neurologists anticipate that less than 30 percent of their use of emerging oral agents --- Merck Serono's oral cladribine, Novartis/Mitsubishi Pharma's fingolimod (FTY-720) --- for the treatment of multiple sclerosis will be in the first line. Surveyed neurologists expect to use these drugs in patients who refuse injectables, filling an important unmet need and potentially increasing the drug-treatment rate in newly diagnosed patients.

"Surveyed neurologists' responses suggest that Biogen Idec's Avonex is more at-risk than Teva's Copaxone of losing share upon the launch of either oral cladribine or fingolimod, as more physicians cite Avonex as having potential for being replaced by either emerging oral agent," stated Amanda Puffer, M.Sc., analyst at Decision Resources. "However, approximately half of the surveyed neurologists who are aware of these therapies are unsure if they will prescribe them, most likely because of uncertainty about these agents' side-effect/safety profiles."

The new report entitled Treatment Algorithms in Multiple Sclerosis also finds that only 38.8 percent of newly diagnosed patients receive a drug within one year of their first diagnosis. This highlights the substantial room for increased uptake of disease-modifying therapies in newly diagnosed patients. While surveyed neurologists indicate they prescribe disease-modifying therapies to the majority of relapsing-remitting patients (the dominant multiple sclerosis subtype), they are less likely to prescribe disease-modifying therapies to patients with clinically isolated syndrome (early-stage multiple sclerosis). This is despite clinical studies indicating that early initiation of disease-modifying therapies can delay progression of the disease, and specifically, delay disability progression.

"Those patients who do not start disease-modifying treatment right away represent an untapped opportunity for marketers of disease-modifying drugs," added Ms. Puffer. "Treatment rates could be improved, especially for patients with early stage disease, through increased awareness among both neurologists and primary care physicians, of the benefits surrounding early treatment initiation. These improvements would facilitate increased use of disease-modifying therapies."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
2. New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option
3. American Legion Anticipates Institute of Medicine Report on Gulf War Veterans
4. Preterm Births Rise 36 Percent Since Early 1980s
5. Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds
6. Leading Healthcare System Decreases MRSA Infection Rate by 53 Percent - Offers Protocol & Educational Materials Free of Charge to Other Organizations
7. Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
8. Velos Set to Clear 50 Percent Market Penetration of Large U.S. Clinical Research Sites by Year End
9. The ED Conversation Dilemma: Forty Percent of Men with ED Dont Talk to Their Doctor, Survey Finds
10. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
11. A Drug With Efficacy Superior to That of Xenical at Inducing Weight Loss Would Earn a 40 Percent Patient Share in the Obesity Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ANKENY, Iowa , 11 de fevereiro de ... a inauguração de sua fábrica de soroalbumina bovina ... Nova Zelândia. A fábrica fica na Ilha Norte ... Loop "), desenvolvido e estabelecido na fábrica da ... Iowa . O projeto e instalação dos ...
(Date:2/11/2016)... 2016 Breast Cancer Therapeutics in Asia-Pacific ... Asia-Pacific (APAC) breast cancer market will experience considerable ... 2021, at a Compound Annual Growth Rate (CAGR) of 8.5%. ... 2021 - states that the Asia-Pacific ... $1.9 billion in 2014 to $3.4 billion by 2021, at ...
(Date:2/11/2016)... , February 11, 2016 Jeffrey ... Worldwide Clinical Trials, will present at this year,s Summit for ... Hyatt Regency in Miami, FL. Zucker ... to optimize study execution, supporting SCOPE,s "Improving Site Study Activation ... place on Thursday, Feb. 25 at 11:05 a.m. ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 11, 2016 , ... Student-doctors from Western University of Health ... Tuesday, February 9, taking one of the final steps in their medical school ... across the country. Of the 103 student-doctors who comprise the College of Osteopathic ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Image ... business to a new market, and it’s the buildings of Nashville that will benefit. ... when I needed to relocate to Nashville, there was no question that I would ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... and women’s health, is pleased to announce the promotions of Allison Kelly to ... team, Steve Catone to executive vice president of North American capital sales, and ...
(Date:2/11/2016)... Australia (PRWEB) , ... February 11, 2016 , ... ... potential ?" motivational speaker, trainer and author Ray Clarke poses a question as ... personal fulfillment . In his book, "Being in the Being" (published by Partridge ...
(Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
Breaking Medicine News(10 mins):